Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy
Top Cited Papers
- 1 June 2004
- journal article
- Published by Springer Nature in Nature
- Vol. 429 (6992) , 629-635
- https://doi.org/10.1038/nature02580
Abstract
The molecular complexity of tissues and the inaccessibility of most cells within a tissue limit the discovery of key targets for tissue-specific delivery of therapeutic and imaging agents in vivo. Here, we describe a hypothesis-driven, systems biology approach to identifying a small subset of proteins induced at the tissue-blood interface that are inherently accessible to antibodies injected intravenously. We use subcellular fractionation, subtractive proteomics and bioinformatics to identify endothelial cell surface proteins exhibiting restricted tissue distribution and apparent tissue modulation. Expression profiling and gamma-scintigraphic imaging with antibodies establishes two of these proteins, aminopeptidase-P and annexin A1, as selective in vivo targets for antibodies in lungs and solid tumours, respectively. Radio-immunotherapy to annexin A1 destroys tumours and increases animal survival. This analytical strategy can map tissue- and disease-specific expression of endothelial cell surface proteins to uncover novel accessible targets useful for imaging and therapy.Keywords
This publication has 38 references indexed in Scilit:
- Molecular Imaging: Looking at Problems, Seeing SolutionsScience, 2003
- Target discoveryNature Reviews Drug Discovery, 2003
- Molecular imaging in living subjects: seeing fundamental biological processes in a new lightGenes & Development, 2003
- Molecular imaging in drug discovery and developmentNature Reviews Drug Discovery, 2003
- Is proteomics heading in the wrong direction?Nature Reviews Molecular Cell Biology, 2003
- Genetics and new approaches to cancer therapyCarcinogenesis: Integrative Cancer Research, 2002
- Scaling down imaging: molecular mapping of cancer in miceNature Reviews Cancer, 2002
- New Drug Targets for Genomic Cancer Therapy Successes, Limitations, Opportunities and Future ChallengesCurrent Cancer Drug Targets, 2001
- Molecular portraits of human breast tumoursNature, 2000
- Drug Discovery: A Historical PerspectiveScience, 2000